Jazz Pharmaceuticals flags ~$755 million IPR&D charge tied to Actio Biosciences deal

Jazz Pharmaceuticals plc disclosed in an 8-K dated October 26, 2026 that it expects a significant one-time expense tied to its purchase of Actio Biosciences, Inc., a deal that closed on September 15, 2026. The company said it currently estimates that its GAAP and non-GAAP results for the third quarter of 2026 will include a pre-tax charge of about $755 million for acquired in-process research and development.¹

That charge carries a direct bottom-line effect. Jazz said the IPR&D expense cannot be deducted for tax purposes and is expected to reduce both GAAP and non-GAAP adjusted earnings per share for the quarter by roughly $11.00 per share.¹

The company cautioned that these numbers are not final. Jazz noted that its results for the quarter ended September 30, 2026 have not yet been finalized and remain subject to its closing procedures, and that actual results could differ from the preliminary estimates given here.¹ The filing added that this estimated, unaudited data is incomplete on its own and should not replace the full GAAP financial statements Jazz will eventually report for the quarter.¹

The 8-K does not include other quarterly financial figures, pipeline updates, regulatory actions, or clinical trial news; it is limited to this estimated charge connected to the Actio transaction. Jazz also included standard forward-looking statement and non-GAAP measure disclosures, noting that these forward-looking statements are estimates and involve risks and uncertainties such that actual results may differ materially.¹ The filing was signed by Philip L. Johnson, Executive Vice President and Chief Financial Officer, dated October 26, 2026.